CPT® Code 82016

1. Indications

The qualitative acylcarnitine test (CPT® Code 82016) is indicated for the following conditions:

• Newborn Screening This test is routinely performed on infants as part of newborn screening programs to identify metabolic disorders related to fatty acid beta-oxidation and organic aciduria.
• Symptoms of Metabolic Disorders The test may also be conducted at any age when symptoms suggestive of fatty acid metabolism disorders are present.

2. Procedure

The procedure for conducting the qualitative acylcarnitine test involves several key steps:

• Step 1: Sample Collection A blood sample is obtained from the patient, which can be done through a venipuncture or a capillary draw. It is important to note that both methods of blood collection are separately reportable, ensuring that the procedure is accurately documented for billing purposes.
• Step 2: Sample Preparation Once the blood sample is collected, it is processed to separate the plasma or whole blood, which is necessary for the subsequent analysis. This step is crucial as it prepares the sample for testing, ensuring that the results will be accurate and reliable.
• Step 3: Testing Methodology The prepared plasma or whole blood is then analyzed using low injection analysis-tandem mass spectrometry. This advanced analytical technique allows for the precise identification and qualitative assessment of acylcarnitines present in the blood sample.
• Step 4: Reporting After the analysis is complete, the results are documented, and the CPT® Code 82016 is reported for each separate specimen obtained. This ensures proper tracking and billing for the test performed.

3. Post-Procedure

Post-procedure care for patients undergoing the qualitative acylcarnitine test is generally minimal, as the test is non-invasive and does not require extensive recovery time. Patients may resume normal activities immediately following the blood draw. However, it is essential to monitor for any potential complications related to the venipuncture or capillary draw, such as bruising or discomfort at the site of the blood collection. The results of the test will be communicated to the healthcare provider, who will interpret the findings in the context of the patient's clinical presentation and determine if further testing or intervention is necessary.